Search

Displaying results 3771 - 3780 of 4433 in total
  1. Drug

    Orgotein

    go.drugbank.com/drugs/DB11444
    ExperimentalVet approved

    Hydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum.

  2. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  3. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with

  4. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding

  5. Drug

    1-Deoxy-D-xylulose 5-phosphate

    go.drugbank.com/drugs/DB02496
    Experimental

    These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.

  6. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  7. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

  8. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  9. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.

  10. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual